Sign up to save your podcasts
Or
Share Carl Schoellhammer: viability is the crucial third pillar in CGT
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Carl Schoellhammer: viability is the crucial third pillar in CGT
In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs).
Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles.
Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/
View all episodes
By Ori BiotechIn this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs).
Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles.
Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/
More shows like Ori Spotlight
View all
Biotech Hangout
17 Listeners